Last reviewed · How we verify
Alfenta (ALFENTANIL)
Alfenta (alfentanil) is a small molecule opioid agonist that targets the mu-type opioid receptor. It was originally developed by AKORN and is now owned by Rising. Alfenta is used for general anesthesia and was FDA approved in 1986. It has a short half-life of 1.6 hours and low bioavailability of 1%. Alfenta is off-patent and has a generic manufacturer.
At a glance
| Generic name | ALFENTANIL |
|---|---|
| Sponsor | Rising |
| Drug class | Opioid Agonist |
| Target | Mu-type opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1986 |
Approved indications
- General anesthesia
Common side effects
- Nausea
- Hypertension
- Vomiting
- Chest wall rigidity
- Bradycardia
- Tachycardia
- Hypotension
- Skeletal muscle movements
- Myoclonic movements
- Headache
Serious adverse events
- Respiratory depression
- Skeletal muscle rigidity
- Apnea
- Anaphylaxis
- Laryngospasm
- Bronchospasm
- Hypercarbia
- Postoperative respiratory depression
- Postoperative confusion
- Postoperative sedation
Drug interactions
- amprenavir
- erythromycin
- fluconazole
- isocarboxazid
- linezolid
- mibefradil
- naltrexone
- phenelzine
- rasagiline
- selegiline
- tranylcypromine
Key clinical trials
- EEG and Pain Monitor Data Under Anesthesia to Study Pharmacodynamic Effects of Opioids and Sedatives (NA)
- Remimazolam for Bronchoscopy in High-Risk Patients (PHASE4)
- A Randomized, Controlled Clinical Trial Comparing Remimazolam Besylate Combined With Alfentanil Versus Propofol Combined With Alfentanil for Anesthesia in Thoracic Surgery (PHASE4)
- Efficacy and Safety of Ciprofol for General Anaesthesia in Patients Undergoing Transcatheter Aortic Valve Replacement (PHASE4)
- The Efficacy of Remimazolam on Incidence of Hypoxia During Sedated Transvaginal Oocyte Retrieval: A Multicenter Randomized Controlled Trial. (NA)
- NoL Index Response to Stimulation in Anesthetized Children (NA)
- Effects of Adding Different Drugs for Preventing Cough Induced by Bronchoscopic Spraying of Local Anesthetics (NA)
- Standardised Drug Provocation Testing in Perioperative Hypersensitivity (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alfenta CI brief — competitive landscape report
- Alfenta updates RSS · CI watch RSS
- Rising portfolio CI